# Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

> **NCT06635785** · PHASE1,PHASE2 · RECRUITING · sponsor: **OncoC4, Inc.** · enrollment: 387 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** AI-081

## Key facts

- **NCT ID:** NCT06635785
- **Lead sponsor:** OncoC4, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-26
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 387 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06635785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06635785, "Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06635785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*